<DOC>
	<DOCNO>NCT00675064</DOCNO>
	<brief_summary>This study examine safety single dos GSK369796 healthy subject , along test examine quickly GSK369796 get blood , long take body get rid .</brief_summary>
	<brief_title>Single-Blind , Placebo-Controlled , Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Antimalarials</mesh_term>
	<criteria>Healthy adult age 18 40 , inclusive . Female subject must nonchildbearing potential include premenopausal female document ( medical report verification ) hysterectomy bilateral oophrectomy postmenopausal define 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/ml . Body weight &gt; 50 kg body mass index ( BMI ) 19 30 kg/m2 : A screening electrocardiogram ( 12lead ECG ) QTc &lt; 450 msec . Troponin I £0.04 ng/mL screen Beckman Access2® AccuTnI™ Troponin I Assay . The subject able understand comply protocol requirement , instruction restriction . Signed date write informed consent prior admission study Healthy adult male females 18 60 year age , inclusive . Whether subject `` healthy '' determine responsible physician , base medical evaluation include history , physical examination , laboratory test , cardiac monitoring . To eligible , female subject must negative pregnancy test ( i.e . serum bhCG test ) : 1. nonchildbearing potential ( i.e . physiologically incapable become pregnant ) . This include premenopausal female document ( medical report verification ) hysterectomy double oophrectomy postmenopausal define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL 6 week postsurgical bilateral oophorectomy without hysterectomy , document hysterectomy tubal ligation sufficient . 2. childbearing potential agrees commit two protocolapproved method contraception , use consistently accordance product label instruction physician ( list protocol ) . Male subject must agree abstain use condom sexual intercourse pregnant lactating female ; use condom/spermicide , addition female partner use another form contraception , IUD , diaphragm spermicide , oral contraceptive , inject able progesterone , sub dermal implant engage sexual intercourse female partner could become pregnant . This criterion must follow time first dose study medication completion follow procedure . Body weight ³ 50 kg ( 110 pound ) men ³ 45 kg ( 99 pound ) woman body mass index ( BMI ) 19 31 . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) bilirubin within reference range screening . Signed date write informed consent prior admission study . The subject able understand comply protocol requirement , instruction protocolstated restriction Any clinically relevant abnormality identify screen history physical exam , screen 12lead surface electrocardiogram ( ECG ) , screen 24holter cardiac monitoring . Any evidence cardiac disease clinically relevant abnormality identify screen echocardiography . Any clinically relevant abnormality clinical safety laboratory test screen . Positive Human Immunodeficiency Virus ( HIV ) antibody , hepatitis B virus surface antigen , hepatitis C virus antibody screen . Significant cardiac history include limited history myocardial infarction , angina , heart failure , cardiomyopathy , arrhythmia , myocarditis , hypertrophy ( atrial ventricular ) , cor pulmonale . Significant central nervous system ( e.g. , seizure ) , pulmonary , metabolic , renal , hepatic gastrointestinal condition history condition , opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial may interfere absorption , distribution , metabolism excretion drug . History sensitivity study medication component thereof . History sensitivity 4aminoquinolines ( e.g. , chloroquine , amodiaquine , piperaquine ) . History sensitivity heparin heparininduced thrombocytopenia , clinical research unit use heparin maintain intravenous cannula patency . Use prescription nonprescription drug , vitamin , herbal dietary supplement within 14 day 5 halflives ( whichever longer ) prior study medication administration , use St. John 's Wort within 28 day prior study medication administration Unless opinion investigator sponsor medication interfere study procedure compromise safety . By exception , volunteer may take paracetamol ( &lt; / 2 grams/day ) 48 hour prior study medication administration . Consumption grapefruit , grapefruit juice , orange juice Seville orange , red wine within 7 day prior administration study medication . Participation clinical study investigational noninvestigational drug within 3 month 5 halflives ( whichever longer ) precede study medication administration . Exposure four new chemical entity within 12 month prior dose . History drug abuse within 6 month study . A positive urine test drug abuse alcohol ( alcohol breath test ) screen predose . History smoking use nicotine containing product within 3 month screen , positive urine cotinine indicative smoking screening . History regular alcohol consumption exceed 14 units/week 2 units/day woman , 21 units/week 3 units/day men , within 6 month screen . One unit equivalent halfpint beer 1 measure spirit 1 glass wine . An unwillingness male subject abstain sexual intercourse pregnant lactate woman , unwillingness male subject use condom/spermicide , addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation , engage sexual intercourse female partner could become pregnant . This criterion must follow time study medication administration 84 day later . Donation blood excess 500 mL within 90 day prior dose . An unwillingness comply lifestyle and/or dietary restriction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>safety</keyword>
	<keyword>single ascend dose ,</keyword>
	<keyword>Healthy volunteer ,</keyword>
</DOC>